PE20091683A1 - Nuevos derivados 258 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona - Google Patents
Nuevos derivados 258 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-onaInfo
- Publication number
- PE20091683A1 PE20091683A1 PE2009000455A PE2009000455A PE20091683A1 PE 20091683 A1 PE20091683 A1 PE 20091683A1 PE 2009000455 A PE2009000455 A PE 2009000455A PE 2009000455 A PE2009000455 A PE 2009000455A PE 20091683 A1 PE20091683 A1 PE 20091683A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrimidin
- thiazolo
- ethyltio
- methylpentan
- hydroxy
- Prior art date
Links
- DCSLKYLPOSSKFY-UHFFFAOYSA-N 3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1=NC=C2SC(=O)NC2=N1 DCSLKYLPOSSKFY-UHFFFAOYSA-N 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 abstract 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE TIAZOLO[4,5-D]PIRIMIDIN-2(3H)-ONA DE FORMULA (I) DONDE R1 ES CH3 O C2H5; R2 Y R3 SON CADA UNO H O CH3; R4, R5, R6 Y R7 SON CADA UNO H, CH3 O C2H5. SON COMPUESTOS PREFERIDOS: 7-[(R)-1-HIDROXI-4-METILPENTAN-2-ILAMINO]-5-[1-(PIRIDIN-2-IL)ETILTIO]TIAZOLO[4,5-d]PIRIMIDIN-2(3H)-ONA,7-[(R)-1-HIDROXI-4-METILPENTAN-2-ILAMINO]-5-[1-(2,4-DIMETILPIRIDIN-2-IL)ETILTIO]TIAZOLO[4,5-d]PIRIMIDIN-2(3H)-ONA, 7-[(R)-1-HIDROXI-4-METILPENTAN-2-ILAMINO]-5-[1-(2-METILPIRIDIN-2-IL)ETILTIO]TIAZOLO[4,5-d]PIRIMIDIN-2(3H)-ONA, 7-[(R)-1-HIDROXI-4-METILPENTAN-2-ILAMINO]-5-[1-(3-METILPIRIDIN-2-IL)ETILTIO]TIAZOLO[4,5-d]PIRIMIDIN-2(3H)-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CX3CR1 SIENDO UTILES EN EL TRATAMIENTO DEL ACCIDENTE CEREBROVASCULAR O LA LESION CEREBRAL TRANSITORIA (TBI)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3946308P | 2008-03-26 | 2008-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091683A1 true PE20091683A1 (es) | 2009-12-04 |
Family
ID=41114185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000455A PE20091683A1 (es) | 2008-03-26 | 2009-03-26 | Nuevos derivados 258 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090247555A1 (es) |
| AR (1) | AR071036A1 (es) |
| CL (1) | CL2009000750A1 (es) |
| PE (1) | PE20091683A1 (es) |
| TW (1) | TW200944533A (es) |
| UY (1) | UY31734A (es) |
| WO (1) | WO2009120140A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6076913B2 (ja) | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | 癌からの転移を阻害する方法 |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| JP5872105B2 (ja) | 2013-03-12 | 2016-03-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン−３−イル酢酸誘導体の塩およびその結晶 |
| US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
| GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| AU2023362450A1 (en) | 2022-10-19 | 2025-05-29 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3 cr1 |
| WO2025219939A1 (en) | 2024-04-17 | 2025-10-23 | Astrazeneca Ab | Salts and polymorphs of cx3cr1 modulators |
| WO2025219947A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Thio-substituted 1,3,5-triazine cx3cr1 modulators |
| WO2025219950A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Small molecule cx3cr1 modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| GB0221828D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| TW200820973A (en) * | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
-
2009
- 2009-03-23 AR ARP090101036A patent/AR071036A1/es unknown
- 2009-03-25 WO PCT/SE2009/050310 patent/WO2009120140A1/en not_active Ceased
- 2009-03-25 UY UY0001031734A patent/UY31734A/es not_active Application Discontinuation
- 2009-03-26 US US12/411,463 patent/US20090247555A1/en not_active Abandoned
- 2009-03-26 PE PE2009000455A patent/PE20091683A1/es not_active Application Discontinuation
- 2009-03-26 TW TW098109979A patent/TW200944533A/zh unknown
- 2009-03-26 CL CL2009000750A patent/CL2009000750A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2009000750A1 (es) | 2010-10-15 |
| AR071036A1 (es) | 2010-05-19 |
| UY31734A (es) | 2009-11-10 |
| US20090247555A1 (en) | 2009-10-01 |
| TW200944533A (en) | 2009-11-01 |
| WO2009120140A1 (en) | 2009-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091683A1 (es) | Nuevos derivados 258 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona | |
| CL2008003290A1 (es) | Compuestos derivados heterociclicos, moduladores de gamma secretasa; composicion farmaceutica; y uso para el tratamiento de la enfermedad de alzheimer, sindrome de down, deterioro cognitivo leve, glaucoma, angiopatia amiloide cerebral, demencia, microgliosis, inflamacion del cerebro, entre otros. | |
| PE20120418A1 (es) | DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP) | |
| CL2008002911A1 (es) | Compuestos derivados de [arilo heteroarilo]-[1-piperidinilo susutituido]metanona, antagonista del receptor ccr-2, ccr-3, ccr-5; proceso de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de la enfermedad arterial periferica oclusiva e isquemia critica de las extremidades, entre otras. | |
| ES2299896T3 (es) | Derivados de benzazepina como antagonistas h3 de histamina. | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20090651A1 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 | |
| PE20110833A1 (es) | Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio | |
| CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
| CL2008002864A1 (es) | Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros. | |
| PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
| PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
| PE20110852A1 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| NI200900193A (es) | Antagonistas piridil piperidina del receptor de orexina | |
| PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
| AR061580A1 (es) | Profarmacos de 5- amino-3-(3'- desoxi- beta-d - ribofuronosil)-tiazolo [4 ,5- d] pirimidin-2,7- diona | |
| CR9622A (es) | Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3 | |
| PE20071023A1 (es) | Azaciclilaminas-n-sustituidas como antagonistas de histamina-3 | |
| PE20151559A1 (es) | Nuevos derivados de piridina | |
| PE20071164A1 (es) | Compuestos heterociclico fusionado como antagonista del receptor mineralocorticoide | |
| PE20091811A1 (es) | DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1 | |
| CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. | |
| PE20110777A1 (es) | Nuevas lactamas como inhibidores de beta secretasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |